We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -22.00 | -0.18% | 12,004.00 | 12,004.00 | 12,006.00 | 12,144.00 | 11,960.00 | 12,070.00 | 358,148 | 11:05:07 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.24 | 186.02B |
From Apr 2019 to Apr 2024
TIDMAZN
RNS Number : 0963O
AstraZeneca PLC
16 August 2017
16 August 2017 07:00 BST
ASTRAZENECA NON-EXECUTIVE DIRECTOR RETIREMENT
AstraZeneca announced that, on 31 August 2017, Bruce Burlington will retire as a Non-Executive Director of AstraZeneca PLC and as a member of the Audit Committee, the Nomination and Governance Committee, and from his role as Chairman of the Science Committee.
Dr Burlington joined the Board in 2010 and will have served for seven years when he steps down.
Leif Johansson, Chairman of AstraZeneca, said: "Bruce has been an exemplary Director who has made a significant contribution to the Board's work over many years. We have valued his insightful and frank participation as a Board member, and Chairman of the Science Committee during a period of innovation-led transformation at AstraZeneca. His diligence and commitment to the work of the Audit Committee and the Nomination and Governance Committee should also be acknowledged. On behalf of all Board members, we will miss Bruce as a colleague and send him our very best wishes for the future."
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations Esra Erkal-Paler UK/Global +44 203 749 5638 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Matt Kent UK/Global +44 203 749 5906 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Nick Stone Respiratory, Brilinta +44 203 749 5716 Christer Gruvris Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711 US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFSESIFWSESA
(END) Dow Jones Newswires
August 16, 2017 02:00 ET (06:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
